Biomarkers in Gynecologic Tumors
- By Selim Afsar1
-
View Affiliations Hide Affiliations1 Department of Obstetrics and Gynecology, Balkesir University Medical Faculty, Balikesir,Turkey
- Source: Biomarkers in Medicine , pp 16-36
- Publication Date: August 2022
- Language: English
Biomarkers in Gynecologic Tumors, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815040463/chap2-1.gif
Gynecologic malignancies are one of the most frequent cancers amongst women. Biomarkers are crucial for the differential diagnosis of adnexal masses; however, their potential for diagnosis is limited. In the era of difficulty in ovarian cancer screening, novel biomarkers are defined, but CA125 still remains the most valuable one. Circulating tumor DNAs, DNA hypermethylation, metabolites, microRNAs, and kallikreins have recently turned out as ovarian cancer biomarkers and are being applied to clinical practice. For uterine cancer, genomic classification has now been described, it will be used as a prognostic tool. In this chapter, we describe ovarian, endometrial, and cervical cancer biomarkers in detail.
-
From This Site
/content/books/9789815040463.chap2dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
